-
-
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
2023-07-27
·HANQUYOUis the China-developed biosimilar with the mostmarketing approvals, covering41 countries and regions·Thelaunch ofHANQUYOUkicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies·Henlius will continue to expand its overseas footprint and accelerate the delivery of
-
-
Henlius completed the phase 1/2 clinical trial of HLX04-O for the treatment of Ophthalmic Diseases
2023-07-26
Shanghai, China, 26 July 2023 - Shanghai Henlius Biotech, Inc. (2696.HK) announced a phase 1/2 clinical trial of HLX04-O, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the company and Essex, has been completed in patients with wet age-related macular degeneration (wAMD). The results of this study demonstrated the good safety&
-
-
New Exhibition | “KENGO KUMA: Architecture for the Five Senses” to Officially Open To Public on 21 July!
2023-07-20
On 20 July 2023,Kengo Kuma’s latest solo exhibition,“Architecture for the Five Senses”officially opened at Fosun Foundation (Shanghai)Based on the new concept of "Architecture for the Five Senses”introduced by the world-renowned architect Kengo Kuma,visitors can explore the new form of future architecturethrough the human senses: sight, hearing, touch, smell&
-
-
Emerging Visionaries Hosts its First National Summit & Ceremony After an Upgrade
2023-07-12
On 11 July 2023,Emerging Visionaries National Summit & Ceremony was held in Shanghai Jiulong Model Middle School. Under the guidance of Shanghai People's Association for Friendship with Foreign Countries (SPAFFC), the event was hosted by Prudential Financial, Inc., Fosun Foundation, Pramerica Fosun Life Insurance and Fosun Trade, and organized
-
-
China's NMPA Accepts Fosun Pharma’s BLA for Innovative Botulinum Toxin Product DAXXIFY® for the Treatment of Cervical Dystonia
2023-07-12
(7 July 2023, Shanghai, China) On 7 July, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma”; stock code: 600196.SH, 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group, announced that the Biologics License Application (“BLA”) for DAXXIFY®(DaxibotulinumtoxinA for injection) for the treatment of cervical dyst
-
-
NUS and PwC Jointly Release Sustainability Counts II, affirming Fosun International’s leading standard in ESG disclosure
2023-07-12
(12July 2023) The National University of Singapore (NUS) Centre for Governance and Sustainability (CGS) and PricewaterhouseCoopers (PwC) Singapore recently jointly released Sustainability Counts II(the “Report”). Based on the principles of Global Reporting Initiative (GRI) and the Task Force on Climate-Related Financial Disclosures (TCFD), the studyfocuses on the an
-
-
Millennium BCP in “Europe’s Climate Leaders 2023” Financial Times and Statista Ranking
2023-07-10
Millennium bcp is considered a European climate leader by the Financial Times and Statista. For the third consecutive year, Millennium is included the “Europe’s Climate Leaders 2023” ranking prepared by the two institutions, with an overall score of 62.2.The ranking was developed by the leading financial newspaper and by Statista - a German company specializing in mar
-
-
Fosun Contributes to Carbon Peak and Carbon Neutrality Acting as a Responsible Global Citizen
2023-07-07
Fosun has been founded for more than 30 years since 1992. Looking back on the past and looking ahead, Fosun always adheres to the original aspiration of “Self-improvement, Teamwork, Performance and Contribution to Society”, striving to make the world a better place because of the presence of Fosun.Standing at a new historical starting point after the 30th yea
-
-
Fosun Pharma Receives WHO Prequalification for Its Second-generation Artesunate for Injection Argesun®
2023-07-07
The second-generation artesunate for injection Argesun® independently developed by Fosun Pharma (600196.SH;02196.HK) was approved by WHO Prequalification(1)(WHO PQ) on 27 June 2023, which can enhance the accessibility of innovative antimalarial drugs and ultimately contribute to saving more lives.The first generation artesunate for injection (brand name Artesun®), independently